C4X Discovery Holdings (FRA:C4J) ROCE % : 228.14% (As of Jan. 2024)

View and export this data going back to 2020. Start your Free Trial

What is C4X Discovery Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. C4X Discovery Holdings's annualized ROCE % for the quarter that ended in Jan. 2024 was 228.14%.

C4X Discovery Holdings ROCE % Historical Data

The historical data trend for C4X Discovery Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4X Discovery Holdings ROCE % Chart

C4X Discovery Holdings Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

ROCE %

Get a 7-Day Free Trial

-178.05

-124.72

-43.05

-66.60

-141.04

C4X Discovery Holdings Semi-Annual Data
	Jul14	Jan15	Jul15	Jan16	Jul16	Jan17	Jul17	Jan18	Jul18	Jan19	Jul19	Jan20	Jul20	Jan21	Jul21	Jan22	Jul22	Jan23	Jul23	Jan24
ROCE %	Get a 7-Day Free Trial															-64.35	-71.85	-77.93	-163.87	228.14

C4X Discovery Holdings ROCE % Calculation

C4X Discovery Holdings's annualized ROCE % for the fiscal year that ended in Jul. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	-15.601	/	( ( (17.187 - 2.775)	+	(10.233 - 2.522) )	/ 2 )
	=	-15.601	/	( (14.412	+	7.711)	/ 2 )
	=	-15.601	/	11.0615
	=	-141.04 %

C4X Discovery Holdings's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Jul. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Jul. 2023 )		(Q: Jan. 2024 )
	=	41.54	/	( ( (10.233 - 2.522)	+	(30.588 - 1.883) )	/ 2 )
	=	41.54	/	( ( 7.711	+	28.705 )	/ 2 )
	=	41.54	/	18.208
	=	228.14 %

(1) Note: The EBIT data used here is two times the semi-annual (Jan. 2024) EBIT data.

C4X Discovery Holdings (FRA:C4J) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

C4X Discovery Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of C4X Discovery Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

C4X Discovery Holdings (FRA:C4J) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4X Discovery Holdings PLC (FRA:C4J) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

C4XD:UK C4J:Germany

Address

53 Portland Street, Manchester One, Manchester, GBR, M1 3LD

Website

https://www.c4xdiscovery.com

C4X Discovery Holdings PLC is a drug discovery and development company. It has various proprietary and synergistic software platforms Taxonomy3, Conformetrix, and 4Sight. Taxonomy3 is a novel in silico platform technology that utilizes proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data. Conformetrix enables rational, accelerated 4D structural drug design using experimental data rather than theoretical data. The 4Sight allows its research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules.

C4X Discovery Holdings (FRA:C4J) Headlines

No Headlines